Noramco, LLC
USPTO PatentsView assignee record - 11 granted patents across 8 technology areas, recorded in grant years 2017–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).
The verdict
According to USPTO PatentsView, Noramco ranks #24,899 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 8 technology areas.
- #24,899
- of 49,997 US assignees by volume
- 35th percentile
- by Innovation Score (30.7/100)
- 20.2
- avg claims per patent
- -43%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R24899 · US Corporation #24,899 · 11 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 11 grants
- MID-PACK #24,899/49,997
- PHOTO-FINISH Nippon Medical…
- CPC-NARROW C07D · 8 areas
- INNOV-THIN 30.7/100
- CLAIMS-DENSE 20.2 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -43% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Nippon Medical School Foundation (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Noramco’s 30.7 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Noramco
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Noramco · this assignee 31
Noramco · this assignee
31 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Noramco's Innovation Score is 30.7/100 (35th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Noramco?
Each dot is one of Noramco’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Noramco’s own 20.2 claims/patent is ABOVE the 10.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Noramco's grants concentrate
Noramco, LLC is a focused PatentsView assignee: 8 CPC subclasses with 90.9% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2018 (3 grants) versus a trough of 2 in 2017. By volume, Noramco sits between Nippon Medical School Foundation and Novita Pharmaceuticals, Inc..
Who files at Noramco's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Nippon Medical Sc…
Nippon Medical School Foundation
11 patents
- Nippon Yusen
Nippon Yusen Kabushiki Kaisha
11 patents
- Nitto Pharmaceuti…
Nitto Pharmaceutical Industries, Ltd.
11 patents
- NMC
NMC, Inc.
11 patents
- Northstar Battery
Northstar Battery Company, LLC
11 patents
- Novasight
Novasight Ltd.
11 patents
- Novatrans Group
Novatrans Group SA
11 patents
- Novita Pharmaceut…
Novita Pharmaceuticals, Inc.
11 patents
- Noramco ◀
Noramco, LLC
11 patents
What this shows Noramco holds 11 patents at rank #24,865, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Noramco
By rank, the assignees closest to #24,865 in granted patent volume.
- Nippon Medical School Foundation #24,861 · 11 patents
- Nippon Yusen Kabushiki Kaisha #24,862 · 11 patents
- Nitto Pharmaceutical Industries, Ltd. #24,863 · 11 patents
- NMC, Inc. #24,864 · 11 patents
- Northstar Battery Company, LLC #24,866 · 11 patents
- Novasight Ltd. #24,867 · 11 patents
- Novatrans Group SA #24,868 · 11 patents
- Novita Pharmaceuticals, Inc. #24,869 · 11 patents
Leaders in C07D (Heterocyclic Compounds)
Other assignees with the most granted patents in Noramco's primary technology class.
Noramco's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
31 35th percentile higher than 35% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 2 | 18.2% |
| 2018 | 3 | 27.3% |
| 2019 | 2 | 18.2% |
| 2020 | 2 | 18.2% |
| 2021 | 2 | 18.2% |
Which technologies does Noramco, LLC patent most?
Top 8 of 8 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Noramco, LLC's patent record in context - here's where to go next.
- Noramco, LLC's lead technology class is C07D (Heterocyclic Compounds), 90.9% of its portfolio - see every assignee active in that class. Explore C07D
- Ranked #24,899 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Noramco, LLC against Nippon Medical School Foundation, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 30.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.